Skip to main content

Table 1 Characteristic of population according to GSU and NGSU group

From: A high high-density lipoprotein level is associated with Gleason score upgrade in Chinese patients diagnosed with high-grade prostate carcinoma

Term

GS = 6

GS = 7

NGSU

GSU

P-value

NGSU

GSU

P-value

Case

20 (38.5%)

32 (61.5%)

 

36 (46.2%)

42 (53.8%)

 

Age

65.60 ± 5.48

65.94 ± 5.71

0.833

67.03 ± 7.03

66.43 ± 5.71

0.684

BMI

24.27 ± 3.07

25.36 ± 2.91

0.207

24.82 ± 3.18

24.61 ± 3.17

0.775

Hypertension

6 (30.0%)

14 (70.0%)

0.389

14 (42.4%)

19 (57.6%)

0.649

Diabetes Mellitus

4 (33.3%)

8 (66.7%)

0.747

8 (53.3%)

7 (46.7%)

0.576

MetS

4 (28.6%)

10 (71.4%)

0.524

10 (41.7%)

14 (58.3%)

0.631

Total-PSA (ng/ml)

10.91 ± 7.97

12.71 ± 14.87

0.621

23.56 ± 27.47

26.16 ± 22.71

0.648

Free-PSA (ng/ml)

1.37 ± 0.90

2.05 ± 3.40

0.424

1.64 ± 1.09

2.29 ± 2.41

0.172

PSA

  

0.999

  

0.245

 PSA ≤ 4

2 (33.3%)

4 (66.7%)

 

0 (0.0%)

3 (100.0%)

 

 PSA > 4

18 (39.1%)

28 (60.9%)

 

36 (48.0%)

39 (52.0%)

 

Free PSA/Total PSA ratio

  

0.739

  

0.662

 ≤ 18%

13 (39.4%)

20 (60.6%)

 

27 (46.6%)

31 (53.4%)

 

 > 18%

4 (30.8%)

9 (69.2%)

 

3 (60.0%)

2 (40.0%)

 

PV (ml)

82.07 ± 42.47

83.68 ± 41.95

0.907

88.77 ± 51.57

73.99 ± 29.62

0.205

PI-RADS

  

0.185

  

0.126

 1

1 (50.0%)

1 (50.0%)

 

0 (0.0%)

1 (100.0%)

 

 2

7 (70.0%)

3 (30.0%)

 

8 (57.1%)

6 (42.9%)

 

 3

2 (22.2%)

7 (77.8%)

 

3 (30.0%)

7 (70.0%)

 

 4

9 (34.6%)

17 (65.4%)

 

18 (60.0%)

12 (40.0%)

 

 5

1 (20.0%)

4 (80.0%)

 

7 (30.4%)

16 (69.6%)

 

Number of biopsy cores

24.10 ± 0.45

24.16 ± 0.52

0.689

23.33 ± 2.65

22.62 ± 4.20

0.381

Rate of positive cores in biopsy

0.18 ± 0.13

0.21 ± 0.17

0.384

0.29 ± 0.19

0.38 ± 0.22

0.066

Clinical stage

  

0.576

  

0.345

 T1

2 (66.7%)

1 (33.3%)

 

2 (66.7%)

1 (33.3%)

 

 T2

16 (37.2%)

27 (62.8%)

 

30 (47.6%)

33 (52.4%)

 

 T3

2 (33.3%)

4 (66.7%)

 

3 (27.3%)

8 (72.7%)

 

Triglyceride (mg/dL)

1.79 ± 1.40

1.65 ± 1.95

0.791

1.37 ± 0.87

1.44 ± 0.92

0.773

HDL-C (mg/dL)

1.13 ± 0.16

1.17 ± 0.40

0.658

1.08 ± 0.20

1.20 ± 0.28

0.044

Lymphocyte counts (× 109/L)

1.58 ± 0.52

1.46 ± 0.82

0.563

1.42 ± 0.86

1.55 ± 0.71

0.441

Percentage of lymphocyte (%)

26.44 ± 9.02

19.56 ± 13.26

0.031

20.63 ± 12.74

19.85 ± 12.04

0.783

Neutrophile counts (× 109/L)

4.13 ± 1.69

5.80 ± 3.13

0.016

5.69 ± 3.42

6.84 ± 3.22

0.133

Percentage of neutrophile (%)

64.03 ± 11.94

69.42 ± 18.24

0.204

71.91 ± 14.56

69.10 ± 17.91

0.454

NLR

3.38 ± 3.50

6.84 ± 7.61

0.031

6.77 ± 8.29

8.46 ± 14.11

0.530

Hb (g/L)

137.65 ± 9.70

130.31 ± 17.46

0.057

132.39 ± 14.64

128.12 ± 17.40

0.249

  1. Significant value was in bold
  2. GSU Gleason score upgrading, PSA prostate-specific antigen, PV prostate volume, PI-RADS prostate imaging reporting and data system, HDL-C high-density lipoprotein cholesterol, Hb hemoglobin, ISUP International Society of Urological Pathology
  3. aFisher’s exact test